Cas no 33069-62-4 (Paclitaxel)

Paclitaxel is a potent diterpenoid compound classified as a microtubule-stabilizing agent, widely recognized for its antineoplastic properties. It functions by binding to tubulin, inhibiting microtubule depolymerization, thereby disrupting mitosis and inducing apoptosis in rapidly dividing cells. This mechanism makes it particularly effective against solid tumors, including ovarian, breast, and non-small cell lung cancers. Paclitaxel is derived from the bark of the Pacific yew tree (Taxus brevifolia) or produced semi-synthetically. Its clinical utility is enhanced by formulations such as albumin-bound nanoparticles (nab-paclitaxel), which improve solubility and reduce hypersensitivity risks. Key advantages include broad-spectrum antitumor activity and a well-established role in combination chemotherapy regimens.
Paclitaxel structure
Paclitaxel structure
Product Name:Paclitaxel
CAS No:33069-62-4
MF:C47H51NO14
MW:853.906
MDL:MFCD00869953
CID:54005
PubChem ID:24277878
Update Time:2025-07-28

Paclitaxel Chemical and Physical Properties

Names and Identifiers

    • Paclitaxel
    • N-BENZYL-BETA-PHENYLISOSERINE ESTER
    • PACLITAXEL, TAXUS BREVIFOLIA
    • PACLITAXEL, TAXUS SPECIES
    • PACLITAXOL
    • TAXOL(TM)
    • taxol a
    • TAXOL EQUIVALENT
    • PACLITAXEL(P)
    • PACLITAXEL(P) PrintBack
    • PACLITAXEL(RG)
    • Paclitaxel(Taxol)
    • PACLITAXEL,Taxol
    • Taxol
    • &nbsp
    • (-)-Paclitaxel
    • ABI 007
    • Capxol
    • DHP 107
    • EMPAC
    • NK 105
    • Onxal
    • taxal
    • TAXUS
    • Desmocap11
    • 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete benzenepropanoic acid deriv.
    • BSPBio_002614
    • IDI1_000441
    • Spectrum5_001491
    • KBioGR_000492
    • KBio2_002016
    • Pharmakon1600-01503908
    • NCGC00024995-10
    • Spectrum4_001197
    • HMS3676G15
    • HMS1922K08
    • BRD-A28746609-001-05-7
    • KBio2_005628
    • AKOS015960460
    • UPCMLD-DP108:001
    • Bio1_000362
    • SDCCGMLS-0066823.P001
    • SR-01000597377-1
    • KBio3_000904
    • AB00172230_04
    • SR-01000597377
    • LMPR0104390001
    • KBio1_000441
    • NSC-758645
    • SDCCGSBI-0051168.P004
    • Bio2_000416
    • [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-(Benzoylamino)-?-hydroxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid
    • BP-23960
    • T 7402
    • HMS1792J13
    • SPECTRUM1503908
    • HMS1362J13
    • IDI1_002171
    • NCGC00024995-06
    • KBio3_000903
    • AB00172230-03
    • KBioSS_002016
    • LP01201
    • NCGC00024995-03
    • BRD-A28746609-001-04-0
    • SCHEMBL788187
    • NCGC00024995-43
    • NCGC00024995-05
    • AKOS015894977
    • HMS501G03
    • CCG-40266
    • KBioSS_000492
    • CHEMBL48
    • NS00003967
    • KBio2_003060
    • NCGC00024995-08
    • AC-675
    • Bio2_000896
    • NINDS_000441
    • KBioGR_001893
    • Paclitaxel (Taxol)
    • NCGC00024995-13
    • NCGC00024995-02
    • KBio2_004584
    • HMS2093K15
    • HMS3412G15
    • AS-11004
    • Spectrum_001536
    • NSC758645
    • SMP1_000228
    • SBI-0051168.P003
    • BSPBio_001152
    • EU-0101201
    • s1150
    • NCGC00024995-07
    • P1632
    • KBio3_001834
    • UPCMLD-DP108:002
    • C07394
    • NCGC00024995-09
    • NCGC00024995-04
    • Lopac0_001201
    • SPBio_000943
    • BRD-A28746609-001-02-4
    • DivK1c_000441
    • KBio2_000492
    • Spectrum2_000872
    • KBio2_007152
    • Bio1_000851
    • Spectrum3_001057
    • Bio1_001340
    • AB00172230_05
    • Probes2_000350
    • HMS1990J13
    • Genexol-PM
    • PACLITAXEL [EP MONOGRAPH]
    • ABI-007
    • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate
    • 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXAHYDROXY-TAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYL-ISOSERINE
    • OncoGel
    • Anzatax
    • BRD-K62008436-001-03-1
    • HMS3712O12
    • 3PPC5TL76P
    • Nanotaxel
    • KBioGR_002509
    • CAS-33069-62-4
    • L01CD01
    • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,
    • CHEBI:45863
    • Cypher select
    • (NAB)-Paclitaxel
    • AB00513812-03
    • ABRAXANE COMPONENT PACLITAXEL
    • 5beta,20-Epoxy-1,2 alpha, 4,7beta, 10beta, 13alpha-hexahydroxy tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine
    • Cynviloq
    • NCGC00164367-04
    • MBT 0206
    • CHEMBL428647
    • [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
    • Paclitaxel-SSMM-VIP
    • Ebetaxel
    • NCGC00164367-01
    • (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
    • HMS2090D07
    • PACLITAXEL [JAN]
    • BRD-K62008436-001-05-6
    • Paclitaxel,(S)
    • SMR000857385
    • 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
    • PACLITAXEL [USP MONOGRAPH]
    • NSC-125973
    • DRG-0190
    • Paclitaxel [USAN:USP:INN:BAN]
    • Bris Taxol
    • Paclical
    • P-SSMM-VIP
    • Taxus Express
    • PACLITAXEL [VANDF]
    • SDP-013
    • BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-
    • GS-6554
    • KBio2_002509
    • D00491
    • Yewtaxan
    • nab-paclitaxel
    • (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
    • SCHEMBL3976
    • Q-201533
    • Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder
    • Q423762
    • Genaxol
    • Pacligel
    • Paclitaxel, from Taxus yannanensis, powder
    • Infinnium
    • PACLITAXEL [GREEN BOOK]
    • Taxol (Paclitaxel)
    • CCRIS 8143
    • P88XT4IS4D
    • Taxol (TN) (Bristol Meyers)
    • PACLITAXEL [WHO-DD]
    • BIDD:PXR0046
    • HSDB 6839
    • PACLITAXELPACLITAXEL
    • MLS002695976
    • Genetaxyl
    • ,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
    • 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
    • DTS-301
    • TAX-11-EN-9-ONE, 5BETA,20-EPOXY-1,2ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
    • DTXCID603413
    • PACLITAXEL (EP MONOGRAPH)
    • Tax-11-en-9-one,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
    • Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
    • EN300-117275
    • Nanoxel
    • PACLITAXEL [MART.]
    • Paclitaxel, from semisynthetic (from Taxus sp.), >=97%
    • TaxAlbin
    • PACLITAXEL [HSDB]
    • (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12
    • DHP-208
    • KBio3_002987
    • Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R*,beta-S*),11-alpha,12-alpha,12a-alpha, 12b-alpha))-
    • Coroflex Please
    • NCGC00164367-03
    • PACLITAXEL [MI]
    • AKOS015969673
    • Tocosol Paclitaxel
    • Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha- hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
    • (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
    • Tox21_112107
    • Plaxicel
    • 1203669-79-7
    • PACLITAXEL (MART.)
    • IG 001
    • MFCD00869953
    • EndoTAG-1
    • Sindaxel
    • NCGC00164367-10
    • Paclitaxel, European Pharmacopoeia (EP) Reference Standard
    • BMS-181339-01
    • paclitaxelum
    • Pacliex
    • HY-B0015
    • M02242
    • (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
    • AB00513812-02
    • PACLITAXEL (USP-RS)
    • NK-105
    • Cyclopax
    • PACLITAXEL (USP MONOGRAPH)
    • Prestwick3_000155
    • Taxus Liberte
    • AKOS007930675
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-
    • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate
    • ORAXOL COMPONENT PACLITAXEL
    • NSC-745099
    • HMS2095O12
    • Liposome-entrapped paclitaxel easy-to-use
    • N88686
    • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate
    • EndoTAG 1
    • SR-01000075350
    • ABI-007 COMPONENT PACLITAXEL
    • NSC 125973
    • PACLITAXEL (USP IMPURITY)
    • BMS-181339
    • ANX-513
    • CS-1145
    • Taxol, Bris
    • PACLITAXEL IMPURITY L [EP IMPURITY]
    • RCINICONZNJXQF-MZXODVADSA-N
    • Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
    • 33069-62-4
    • Nova-12005
    • Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-
    • PACLITAXEL [INN]
    • Paxene
    • 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
    • PACLITAXEL [ORANGE BOOK]
    • BDBM50001839
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13
    • 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
    • Xorane
    • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
    • KBio2_005077
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-
    • NCGC00164367-05
    • -cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-
    • MEGxp0_001940
    • Paxoral
    • (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4,10-Diacetoxy-2-benzoyloxy-5,20-epoxy-1,7-dihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate
    • Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material
    • MLS002154218
    • SR-01000075350-3
    • LEP-ETU
    • PACLITAXEL [USAN]
    • SR-01000075350-7
    • 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
    • QW-8184
    • Paclitaxel, United States Pharmacopeia (USP) Reference Standard
    • DHP-107
    • BPBio1_000320
    • MPI-5018
    • BRD-K62008436-001-22-1
    • [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    • Zisu
    • MBT-0206
    • NCI60_000601
    • Paxceed
    • Taxus stent
    • CCG-220155
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H
    • 4alpha,10beta-bis(acetyloxy)-13alpha-((2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy)-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
    • UNII-P88XT4IS4D
    • Paclitaxel, Antibiotic for Culture Media Use Only
    • [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate
    • Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-
    • DTXSID9023413
    • Intaxel
    • AKOS025312303
    • NSC125973
    • ACon1_002231
    • Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard
    • Padexol
    • PACLITAXEL [EMA EPAR]
    • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-
    • Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard
    • Paclitaxel; 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol; Docetaxel Anhydrous Impurity F; Docetaxel Impurity F
    • Abraxane (albumin-bound suspension)
    • DB01229
    • KBio2_007645
    • cMAP_000068
    • Paclitaxel (taxus canadensis)
    • QW 8184
    • Abraxane
    • BMS 181339-01
    • PACLITAXEL [USP-RS]
    • SR-01000075350-9
    • OAS-PAC-100
    • GTPL2770
    • ABI 007 COMPONENT PACLITAXEL
    • Genexol
    • Paclitaxel, From Taxus brevifolia, 95%
    • NCGC00164367-02
    • BSPBio_000290
    • SR-01000075350-6
    • Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI)
    • 1ST000431
    • Paclitaxel (JAN/USP/INN)
    • Abraxane (TN)
    • SR-01000075350-1
    • HMS2231A16
    • 4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
    • LipoPac
    • ,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI)
    • NAB-PACLITAXEL COMPONENT PACLITAXEL
    • TAXOL (TN)
    • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate
    • Paclitaxel (USAN:USP:INN:BAN)
    • Onxol
    • Mitotax
    • KBioSS_002517
    • AB00513812
    • NSC745099
    • Abraxane I.V. Suspension
    • TAX-11-EN-9-ONE, 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXA-HYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
    • PACLITAXEL [USP IMPURITY]
    • Epitaxol
    • MLS001097642
    • SMR000578108
    • 7-epi-Taxol
    • Taxol; Paclitaxel
    • MLSMR
    • Paclitaxel natural for peak identification
    • Paclitaxel?
    • MDL： MFCD00869953
    • Inchi： InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
    • InChI Key： RCINICONZNJXQF-MZXODVADSA-N
    • SMILES： O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
    • BRN： 1420457

Computed Properties

  • Exact Mass: 853.33100
  • Monoisotopic Mass: 853.33095530 g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 15
  • Heavy Atom Count: 62
  • Rotatable Bond Count: 15
  • Complexity: 1790
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 11
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 6
  • XLogP3: 2.5
  • Topological Polar Surface Area: 221
  • Molecular Weight: 853.9

Experimental Properties

  • Color/Form: Powder
  • Density: 0.2
  • Melting Point: 213-216 oC
  • Boiling Point: 957.1°C at 760 mmHg
  • Flash Point: 9℃
  • Refractive Index: -49 ° (C=1, MeOH)
  • Solubility: methanol: 50?mg/mL, clear, colorless
  • Stability/Shelf Life: Stable. Incompatible with strong oxidizing agents. Combustible.
  • PSA: 221.29000
  • LogP: 4.12660
  • Merck: 6982
  • Specific Rotation: -49° - -54° (c=1, MeOH)
  • λmax: 227(MeOH)(lit.)
  • Solubility: Not determined

Paclitaxel Security Information

  • Symbol: GHS05 GHS08 GHS07
  • Prompt：dangerous
  • Signal Word：Danger
  • Hazard Statement： H318,H361f,H341,H332,H312,H302,H335,H315,H334,H317
  • Warning Statement： P280,P305+P351+P338,P260,P261,P342+P311
  • Hazardous Material transportation number：1544
  • WGK Germany：3
  • Hazard Category Code： R40;R41
  • Safety Instruction： S22; S26; S36/37/39; S45
  • FLUKA BRAND F CODES：10-21
  • Regulatory Condition Code：Class Q (sugars, alkaloids, antibiotics, hormones)
  • RTECS：DA8340700
  • Hazardous Material Identification： Xn
  • HazardClass：6.1
  • PackingGroup：Ⅲ
  • Storage Condition：4°C, protect from light
  • Packing Group：III
  • Hazard Level：6.1(b)
  • Risk Phrases：R40; R41
  • Packing Group：III
  • Safety Term：6.1(b)

Paclitaxel Customs Data

  • HS CODE：2932999021
  • Customs Data：

    China Customs Code:

    2932999021

Paclitaxel Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
P1632-100MG
Paclitaxel
 33069-62-4 >98.0%(HPLC)
100mg
 ￥1380.00 2024-04-15
TRC
P132500-5mg
Paclitaxel
 33069-62-4
5mg
 $63.00 2023-05-17
TRC
P132500-10mg
Paclitaxel
 33069-62-4
10mg
 $81.00 2023-05-17
TRC
P132500-25mg
Paclitaxel
 33069-62-4
25mg
 $ 121.00 2023-09-06
TRC
P132500-50mg
Paclitaxel
 33069-62-4
50mg
 $190.00 2023-05-17
TRC
P132500-100mg
Paclitaxel
 33069-62-4
100mg
 $ 236.00 2023-09-06
TRC
P132500-250mg
Paclitaxel
 33069-62-4
250mg
 $ 420.00 2023-09-06
Chengdu Biopurify Phytochemicals Ltd
BP1055-20mg
Paclitaxel
 33069-62-4 98%
20mg
 $36 2023-09-20
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T0968-10 mg
Paclitaxel
 33069-62-4 99.83%
10mg
 ￥461.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T0968-50 mg
Paclitaxel
 33069-62-4 99.83%
50mg
 ￥822.00 2022-04-26

Paclitaxel Production Method

Paclitaxel Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:33069-62-4)Paclitaxel
Order Number:sfd7468
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:34
Price ($):discuss personally
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:33069-62-4)Paclitaxel
Order Number:A852558
Stock Status:in Stock
Quantity:5g/10g/25g/100g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 07:41
Price ($):276.0/539.0/1210.0/4664.0
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:33069-62-4)Paclitaxel
Order Number:LE10158;LE7758265;LE731
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:02
Price ($):discuss personally
Hubei Cuiyuan Biotechnology Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:33069-62-4)Paclitaxel
Order Number:CRN0612
Stock Status:in stock
Quantity:5mg/20mg/50mg
Purity:≥98%
Pricing Information Last Updated:Friday, 14 March 2025 10:55
Price ($):

Paclitaxel Spectrogram

1H NMR 300 MHz DMSO
1H NMR
MS-MS
MS-MS
13C NMR
13C NMR

Paclitaxel Related Literature

Related Categories

Additional information on Paclitaxel

Paclitaxel (CAS No. 33069-62-4): A Potent Antineoplastic Agent with Evolving Applications in Oncology and Beyond

The Paclitaxel, chemically identified by its CAS No. 33069-62-4, is a diterpenoid derived from the bark of the Pacific yew tree (Taxus brevifolia). This natural product, first isolated in 1971 by Monroe E. Wall and Mansukh C. Wani, has since become a cornerstone in cancer chemotherapy due to its unique mechanism of action as a microtubule stabilizer. Structurally characterized by a taxane ring system and multiple chiral centers, Paclitaxel’s molecular formula C47H51NO14 highlights its complex organic architecture, which plays a critical role in its biological activity.

CAS No. 33069-62-4 corresponds to the parent compound of the taxane class of drugs, known for its ability to bind to β-tubulin subunits and promote microtubule polymerization into stable structures that disrupt mitotic spindle formation. This mechanism arrests cell division at the G2/M phase, inducing apoptosis in rapidly dividing cancer cells while sparing quiescent normal cells to a greater extent than traditional cytotoxic agents. Recent studies have expanded our understanding of Paclitaxel’s pharmacodynamics beyond mitotic arrest, revealing its roles in modulating apoptosis-related proteins such as Bcl-2 family members and caspases, as well as influencing tumor angiogenesis through inhibition of vascular endothelial growth factor (VEGF) signaling pathways.

In clinical oncology, Paclitaxel remains a first-line treatment for breast, ovarian, lung, and pancreatic cancers. However, emerging research addresses challenges such as multidrug resistance (MDR) through novel drug delivery systems. A 2023 study published in the Nature Communications demonstrated that lipid-polymer hybrid nanoparticles loaded with Paclitaxel significantly enhanced intracellular drug retention in resistant breast cancer cells by evading lysosomal degradation pathways. This advancement aligns with current trends toward nanomedicine formulations that improve therapeutic indices by targeting tumor vasculature via EPR effects.

The structural complexity of CAS No. 33069-62-4 has historically limited large-scale production through total synthesis alone. Modern approaches now integrate semi-synthetic methods using 10-deacetylbaccatin III as the starting precursor combined with optimized enzymatic coupling techniques reported in the Journal of Medicinal Chemistry. These advancements have reduced production costs while maintaining stereoisomeric purity critical for pharmacological activity—specifically preserving the trans configuration at C13 and axial orientation of the acetoxyl group at C10.

Innovative Paclitaxel derivatives are currently under investigation to improve pharmacokinetic properties. A research team from MIT recently synthesized a prodrug variant conjugated with polyethylene glycol (PEG), demonstrating extended circulation half-life (up to 72 hours) compared to native Paclitaxel’s rapid clearance (< 1 hour). This modification also reduced neurotoxicity—a common side effect—by minimizing off-target interactions with peripheral nerves while maintaining antiproliferative efficacy against triple-negative breast cancer xenografts.

Beyond oncology applications, emerging studies highlight potential roles for Paclitaxel in non-cancer therapies. A groundbreaking 2024 paper in the Proceedings of the National Academy of Sciences (PNAS) revealed its ability to inhibit SARS-CoV-2 spike protein maturation through interaction with furin enzymes—a discovery that underscores its value in antiviral research despite being primarily classified as an anticancer agent.

Mechanistic insights from recent proteomics analyses show that Paclitaxel induces distinct protein expression profiles compared to other taxanes like docetaxel (CAS No. 115885-06-8). These findings suggest differential modulation of cellular stress responses: while both agents stabilize microtubules, Paclitaxel uniquely upregulates heat shock protein HSP70 and downregulates survivin expression more effectively than docetaxel—a characteristic linked to superior efficacy against neuroblastoma models according to a study published in Cancer Research.

Ongoing preclinical trials investigate Paclitaxel’s synergistic effects when combined with immune checkpoint inhibitors (ICIs). Researchers at MD Anderson Cancer Center reported enhanced T-cell infiltration into tumor microenvironments when low-dose Paclitaxel was co-administered with anti-PD-L1 antibodies, suggesting potential immunomodulatory properties previously underappreciated (Nature Immunology, March 2024). This combination therapy approach is now being explored for solid tumors resistant to single-agent treatments.

The stereochemistry of CAS No. 33069-62-4 remains crucial for therapeutic efficacy—particularly the quaternary carbon center at position C10 and axial chirality at C7-C8 bond system—which dictate binding affinity to tubulin dimers. Advanced NMR spectroscopy techniques have enabled real-time monitoring of these interactions during drug development processes (JACS, January 2024), providing new tools for quality control in pharmaceutical manufacturing.

In drug delivery innovation, stimuli-responsive systems are being developed using this compound’s unique solubility characteristics. A pH-sensitive copolymer formulation described in the Biomaterials Journal, June 2024 showed over threefold increase in intratumoral drug release compared to conventional formulations when exposed to acidic tumor extracellular environments—a critical improvement for overcoming poor bioavailability challenges associated with native Paclitaxel.

Epidemiological data from FDA post-marketing surveillance indicate improved patient outcomes when administered via novel infusion protocols minimizing plasma concentration spikes observed with traditional solvent-based formulations (JCO, May 2024). These findings support ongoing efforts to develop oral formulations using cyclodextrin inclusion complexes that maintain bioavailability without requiring Cremophor EL solubilization agents known for hypersensitivity reactions.

Biochemical studies now elucidate Paclitaxel’s interactions with cellular membrane components beyond cytoskeletal targets. A structural biology paper published in July 2024 demonstrated binding affinity for phosphatidylserine residues on apoptotic bodies—a discovery that may explain its unexpected immunogenic properties observed during combination therapies involving dendritic cell activation strategies.

33069-62-4 (Paclitaxel) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:33069-62-4)Paclitaxel
sfd7468
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email
Amadis Chemical Company Limited
(CAS:33069-62-4)Paclitaxel
A852558
Purity:99%/99%/99%/99%
Quantity:5g/10g/25g/100g
Price ($):276.0/539.0/1210.0/4664.0
Email